Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
This is an investigator initiated, multicenter, open label, randomized phase 3 study for
subjects with newly diagnosed ITP from ages 1 to less than 18 years old.
Phase:
Phase 3
Details
Lead Sponsor:
Baylor College of Medicine
Collaborators:
Boston Children's Hospital Boston Children’s Hospital University of California, San Francisco